Posted by Michael Wonder on 23 Feb 2022
PHARMAC recommends funding cystic fibrosis medicine Trikafta but needs more funding
23 February 2022 - PHARMAC’s clinical experts are recommending cystic fibrosis drug Trikafta be funded for those aged over 12 has disappointed patient advocates who say it would mean nearly one in five people would miss out.
Last August, the drug buying agency’s Respiratory Advisory Committee recommended Trikafta be funded for all those aged 6 six and older, with high priority.
But a new recommendation from PHARMAC’s more over-arching Pharmacology and Therapeutics Advisory Committee advised Trikafta be funded with medium priority for those over 12 years old.
